Background: Various strategies are being explored to improve outcomes in advanced ovarian cancer. This study evaluated the survival outcomes of a sequential treatment strategy comprising dose-dense weekly chemotherapy, selective adjuvant radiotherapy, and poly(ADP-ribose) polymerase (PARP) inhibitor maintenance following primary debulking surgery. Methods: We retrospectively reviewed 12 patients with newly diagnosed advanced high-grade serous ovarian cancer (HGSOC) who underwent a sequential treatment strategy (debulking surgery followed by dose-dense chemotherapy, selective adjuvant radiotherapy, and PARP inhibitor maintenance) at Kosin University Gospel Hospital between December 2019 and March 2023. Survival outcomes were analyzed using the Kaplan-Meier method, and treatment-related adverse effects were evaluated. Results: All 12 patients achieved complete remission after the sequential treatment strategy. At the cutoff date (June 20, 2025), all patients were alive, with a median follow-up duration of 48.1 months (range, 28.7–66.5 months). The median progression-free survival (PFS) was 43.8 months. Acute toxicities, including bone marrow suppression and alopecia, were transient and manageable. Peripheral neuropathy and extremity edema were observed as persistent late toxicities. Conclusions This study highlights promising outcomes with a multimodal sequential treatment strategy in newly diagnosed advanced HGSOC. All patients remained alive at the time of analysis, and the median PFS reached 43.8 months, suggesting a potential benefit of this sequential approach compared with conventional treatment strategies. Prospective studies are warranted to validate these findings.

Background: Ambient air pollution has been linked to the increasing prevalence of allergic diseases in children. Exposure to air pollution increases the incidence of asthma and allergic rhinitis and is also known to be associated with inhalant allergen sensitization. Methods: From 2011 to 2024, we retrospectively analyzed the medical records of 313 children in Busan, Korea, with asthma and allergic rhinitis who underwent allergen testing for house dust mites (Dermatophagoides pteronyssinus, D. farinae), animal dander, tree pollen, grass pollen, weed pollen, mold (Alternaria alternata), and cockroach. Ambient air pollutant concentrations of O3, SO₂, CO, NO₂, particulate matter (PM) ≤10 µm (PM10) and PM ≤2.5 µm (PM2.5) were obtained from measurement sites located near the residences of the study subjects. Results: Among the 313 subjects, 94 had asthma, 137 had allergic rhinitis, and 82 had combined asthma and allergic rhinitis. In children who experienced allergic rhinitis symptoms, changes in PM10, PM2.5, maximum SO2 concentration, and maximum NO2 concentration showed positive correlations (correlation coefficients, 0.60, 0.56, 0.64, and 0.49, respectively). In cases of allergic rhinitis accompanied by inhalant allergen sensitization, changes in PM10, PM2.5, CO, NO2, maximum SO2 concentration, maximum CO concentration, and maximum NO2 concentration also showed positive correlations (correlation coefficients, 0.64, 0.60, 0.56, 0.49, 0.52, 0.71, and 0.60, respectively). Conclusions In this study, several air pollutants were associated with allergic rhinitis symptoms in children residing in Busan, and a broader range of air pollutants was associated with allergic rhinitis accompanied by inhalant allergen sensitization.

Gout is the most prevalent inflammatory arthritis worldwide and represents a growing global health burden. It arises from hyperuricemia resulting from disordered purine metabolism, leading to monosodium urate (MSU) crystal deposition and recurrent inflammatory arthritis. Although hyperuricemia is the principal risk factor, genetic susceptibility, impaired urate transport, and emerging factors such as the gut microbiota also contribute to disease development. Acute flares are mediated by MSU crystal-induced activation of the NLRP3 inflammasome and subsequent interleukin-1β production, whereas chronic inflammation results in tophus formation and structural joint damage. Gout is closely associated with metabolic syndrome, chronic kidney disease, and cardiovascular disease, which contribute to persistently elevated mortality. Although advances in imaging and pharmacologic therapy have improved diagnosis and management, the real-world use of urate-lowering therapy remains suboptimal. Further research and sustained efforts by healthcare professionals are needed to improve long-term disease control.

Background: Postoperative liver regeneration is essential for maintaining hepatic function. This study evaluated the rate, determinants, and volumetric patterns of early liver regeneration after hemihepatectomy. Methods: A retrospective review was conducted of 50 patients who underwent right or left hemihepatectomy between April 2019 and March 2025. Liver and spleen volumes (SV) were assessed preoperatively, at postoperative day (POD) 1 week, and at POD 3 months. Early liver regeneration rate (LRR) was defined as the percentage increase in remnant liver volume at POD 1 week relative to the preoperative future liver remnant (FLR), and patients were categorized into low (<50%) and high (≥50%) LRR groups. Clinical, biochemical, and volumetric variables were compared, and predictors of regeneration were identified using multivariable analyses. Regeneration patterns were also examined according to whether the FLR/standard liver volume (SLV) ratio was <50% or ≥50%. Results: FLR/SLV was the strongest independent predictor of rapid early liver regeneration (p<0.001). Remnants with FLR/SLV <50% exhibited rapid and sustained regeneration, whereas those with FLR/SLV ≥50% showed slower regrowth that plateaued after reaching approximately 90% of SLV. SV increased at POD 1 week in all patients; however, only the FLR/SLV ≥50% group showed a reduction by POD 3 months, whereas the <50% group maintained elevated volumes. Conclusions FLR/SLV reliably predicts early postoperative liver regeneration. Smaller remnants regenerate more rapidly, whereas persistent splenic enlargement suggests a sustained portal hemodynamic burden. Combined evaluation of FLR/SLV and SV may enhance perioperative risk assessment and surgical planning.

Biliary tract cancer (BTC) is an uncommon, heterogeneous malignancy with increasing incidence and mortality. Most patients present with advanced disease, which limits curative treatment options and contributes to a poor prognosis. Recent advances in molecular profiling and immuno-oncology have substantially reshaped the therapeutic landscape of BTC by providing deeper insight into its molecular and immunological features. In particular, the incorporation of immune checkpoint inhibitors, such as durvalumab and pembrolizumab, into first-line gemcitabine-cisplatin therapy has demonstrated clinically meaningful survival benefits. Phase III trials, including TOPAZ-1 and KEYNOTE-966, reported significant improvements in overall survival and progression-free survival compared with gemcitabine-cisplatin alone, establishing chemoimmunotherapy as a new standard of care for advanced BTC. The advent of targeted therapies has further expanded treatment options. Agents directed against fibroblast growth factor receptor 2 (FGFR2) fusions, isocitrate dehydrogenase 1 (IDH1) mutations, and human epidermal growth factor receptor 2 (HER2) overexpression have enabled precision-based approaches for patients harboring actionable molecular alterations. These developments highlight the critical role of comprehensive molecular profiling in guiding individualized treatment strategies. Despite these advances, important challenges remain, largely because of the relative rarity of BTC and the inherent limitations of small, heterogeneous study populations. Future research should prioritize large-scale, multicenter, prospective trials to optimize therapeutic sequencing and combination strategies. Furthermore, the routine integration of next-generation sequencing into clinical practice is essential to fully realize the potential of molecularly tailored therapies. This review summarizes the latest evidence on immunotherapy and targeted therapy for BTC and discusses their clinical implications for improving patient outcomes.

Bowel preparation is a key determinant of colonoscopy quality; however, inadequate cleansing remains common among patients with overlapping clinical and logistical barriers. In routine practice, preparation failure may prolong procedures, reduce diagnostic confidence, and necessitate early repeat colonoscopy. We review major society guidelines and selected studies addressing bowel preparation in inflammatory bowel disease (IBD), chronic kidney disease (CKD), older adults, chronic constipation, and hospitalized patients. Across these settings, the most consistently supported measures include split-dose administration, completion of the final dose close to the time of colonoscopy in accordance with local fasting and sedation policies, and structured patient instructions reinforced through follow-up communication. A standardized assessment of preparation quality is recommended to support quality improvement and appropriate follow-up. Risk stratification can help identify patients who may benefit from intensified preparation pathways, including those with prior inadequate preparation, severe constipation, frailty, or inpatient status. Safety considerations are particularly important in CKD, in which oral sodium phosphate should be avoided and magnesium-containing agents used cautiously; polyethylene glycol-based solutions are generally preferred. In IBD, regimen selection should also consider endoscopic interpretability because sodium phosphate preparations have been associated with preparation-related mucosal abnormalities that may confound the assessment of subtle inflammatory findings. Among hospitalized patients, system-level barriers often predominate, and protocolized pathways may improve workflow and patient comfort while maintaining cleansing effectiveness. We propose a practical, risk-stratified approach to regimen selection, timing, rescue strategies, and safety monitoring that can be implemented in high-volume clinical practice.

Obesity is a chronic, progressive neuroendocrine disease that warrants a shift toward an “onco-bariatric” treatment paradigm. This study introduces the tri-phasic metabolic obesity (TPMO) framework, which integrates glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with metabolic bariatric surgery (MBS). Recent clinical and economic evidence—including findings from the Indiana multicenter study and the Highmark Health analysis—was reviewed to evaluate the effectiveness of the TPMO model in improving surgical and metabolic outcomes. The TPMO framework streamlines the patient journey through three synergistic phases. In the neoadjuvant phase, a 4–8-week course of GLP-1 RAs reduces liver volume and visceral fat, thereby improving surgical access, provided that treatment is discontinued 1 week before surgery to mitigate aspiration risk. During the core surgery phase, MBS provides a definitive metabolic reset and remains the most cost-effective treatment, yielding an average savings of $11,689 per patient over 2 years compared with medication alone. In the adjuvant phase, pharmacotherapy—used by 17.2% of post-bariatric patients—counteracts metabolic adaptation and supports sustained weight loss, while a high-protein intake (≥1.2 g/kg/day) is essential for preserving lean body mass. The TPMO framework represents a precision-based, synergistic standard of care designed to promote durable, cost-effective long-term metabolic health within the onco-bariatric paradigm.

Primary adrenal leiomyosarcoma (PAL) is an aggressive, rare tumor that is frequently diagnosed at an advanced stage. We report the case of a 65-year-old female patient with hypertension who presented with stabbing lower abdominal pain and unintentional weight loss. Abdominal computed tomography (CT) demonstrated a 10.4×8.2×8.1 cm heterogeneous left adrenal mass without biochemical evidence of hormonal hypersecretion. Retroperitoneal left adrenalectomy was performed without complications, and histopathological examination confirmed a moderately differentiated adrenal leiomyosarcoma. The patient was followed at the outpatient oncology clinic for 5 years with no evidence of recurrence. Seven years after the initial surgery, a newly detected left suprarenal mass was identified on imaging. Abdominal CT revealed a new, well-circumscribed 7.1×6.4×6.2 cm heterogeneous mass. Laparoscopic resection of the recurrent mass was performed. Pathological examination again revealed a moderately differentiated leiomyosarcoma with positive surgical margins but no lymphovascular invasion. Immunohistochemical staining was positive for smooth muscle actin, desmin, h-caldesmin, neuron-specific enolase, and synaptophysin, findings consistent with recurrent adrenal leiomyosarcoma. This case demonstrates that PAL can recur locally after prolonged disease-free intervals, underscoring the importance of extended surveillance, potentially beyond 10 years.

Background: The National Health Screening Program for Infants and Children (NHSPIC) provides nationwide early detection of developmental issues. However, evidence regarding long-term national trends and regional disparities remains limited. We examined 14-year variations in screening participation and abnormal screening results. Methods: We analyzed nationally aggregated NHSPIC data from the Korean Statistical Information Service for the period 2010‒2023. Outcomes included annual screening participation rates and the prevalence of any abnormal overall screening result. Abnormal results were defined as “Caution” or “Follow-up needed,” based on integrated assessments of growth and nutrition, developmental screening, sensory function, and oral health. Temporal trends were assessed using joinpoint regression to estimate annual percent changes and to identify statistically significant change points. Regional risk ratios and risk differences were calculated using national estimates for reference. Results: National screening participation increased from 50.0% in 2010 to 87.1% in 2021, followed by a decline to 76.7% in 2023. The prevalence of any abnormal overall screening result increased from 8.6% to 19.3%, largely driven by a nearly threefold increase in the “Follow-up needed” category, from 3.0% to 8.8%. Across 17 regions, participation rates ranged from 66.9% to 79.7%, and abnormal result prevalence ranged from 11.4% to 18.3%, indicating persistent geographic disparities. Conclusions Over a 14-year period, NHSPIC coverage expanded substantially but declined in recent years, while regional disparities persisted in both participation and abnormal screening results. These patterns underscore the need for targeted regional strategies to improve access, strengthen follow-up systems, and support equity-oriented monitoring of early childhood screening outcomes.